Neeraj Agarwal: The 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +/- durvalumab in MIBC

Neeraj Agarwal shared a post on X:

“Breaking news (practice changing) from ESMO24, Tom Powles presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +|- durvalumab in MIBC bladder cancer  Significant improvement in DFS (HR 0.68) and OS (HR 0.75) with durvalumab.”

Source: Neeraj Agarwal/X

More posts featuring Neeraj Agarwal and Tom Powles on OncoDaily.

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.

Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.

Thomas Powles specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.

His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.